What this study is
The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.
What's being tested
- Psilocybin
Intervention · DRUG
25 mg
- Placebo
Intervention · DRUG
Placebo capsule
Study details
- Sponsor
- Yale University
- Conditions
- Loneliness · Grief
- Enrolling
- 51 people
- Starts
- 2026-08-31
- Est. completion
- 2031-12-15
- Design
- Triple-blind, randomized, parallel groups, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years – 65 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Medically healthy
- Ability to provide consent
- High loneliness defined by the UCLA-3 Loneliness Scale
- Willingness to comply with all study procedures and availability for the duration of the study
You can't join if
- Any unstable medical condition, psychiatric disorder, or circumstance that, in the opinion of the investigator, could compromise participant safety, interfere with study participation, or hinder the participant's ability to comply with study procedures and requirements
- Positive pregnancy test or women who are breastfeeding
- Any contraindication to MRI such as a pacemaker or metal implants
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openConnecticut Mental Health Center
New Haven, Connecticut, United States
- Anahita Bassir Nia, MD · Contactanahita.bassirnia@yale.edu
- Anahita Bassir Nia, MD · Principal investigator
Study team
Sponsor
Yale University
Study ID 2000041536
Principal investigator
Anahita Bassir Nia, MD
Yale University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.